News and Events
Today, CADTH has issued final recommendations for:
Indications: transthyretin-mediated amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.
Rituximab to Treat Primary Membranous Nephropathy
Call for Feedback: 2020-02-13
Feedback Due By: 2020-02-28
Consultation Document: Proposed Project Scope
Product Type: Health Technology Assessment
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
View all News
The opioid crisis continues to devastate families and communities across Canada. According to the Public Health Agency of Canada, an estimated 12,800 Canadians died from an apparent opioid-related overdose between January 2016 and March 2019. This is a complex issue that requires a compassionate, multi-faceted, evidence-base...
Because of the prevalence and burden of chronic pain, and the associated opioid crisis in our country, health professionals are looking for non-pharmacological treatment options to recommend to their patients. Join CADTH for a webinar on the current evidence on acupuncture for chronic non-cancer pain. The target audience for this presentation is...
April 18, 2020 - April 21, 2020
Join us in Toronto for the 2020 CADTH Symposium.
Connect with Canadian and international experts in the objective assessment and evaluation of health technologies for three days of education, information sharing, and networking.
Mark your calendar:
2020 CADTH Symposium
April 18 to 21, 2020
Sheraton Centre Toronto
Watch for m...
View all Events